Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$1.67
▼ $0.02 (-1.2%)
Market data updated: 09/26 07:52 AM
Fundamentals updated: 09/26/2026
News analyzed: 09/26/2026
Market Cap
$302.40M
Day Range
$1.64 - $1.78
52-Week Range
$0.44 - $3.04
Beta
—
Next Earnings
11.11.2026
Support
$1.63
Resistance
$2.36
IPSC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+242.2% (1Y)
Strengths: 6/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 1556.8%
Growth
Biggest negative driver
Operating margin
Operating margin: -15.8% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
42
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
58
Value
50
Momentum
13
Risk
40
Sentiment
56
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Century Therapeutics, Inc. has centered on its financial performance and progress with its lead experimental diabetes therapy, CNTY-813. The company reported a second-quarter loss per share ($0.17) exceeding analyst estimates, raising concerns about profitability. Meanwhile, positive preclinical data for CNTY-813—highlighting durable glucose control, immune evasion, and scalable manufacturing—garnered attention, with presentations planned at major scientific conferences like EASD 2026 and the Breakthrough T1D Congress. Analysts at Mizuho upgraded the stock to *Outperform* with an $8 price target, while broader market focus included scrutiny of its cash burn situation.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Century Therapeutics, Inc.. News trend score: 56. Reason: 3 of the last 12 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
31
🎯 Conviction (vs. Emotion)
80
Psychology
66
Fundamentals
30
Technical
13
Valuation
50
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-28%
Market Narrative
35
Fundamental Reality
80
Narrative Gap
-45
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for IPSC strongly suggests herding, as its recent decline (-1.4%) mirrors peer movements (-1.7%) without extreme volatility or sentiment extremes. Overconfidence (score 5) hints at traders overvaluing recent momentum (+3.0%) relative to fundamentals, while FOMO and euphoria remain subdued. The dominant narrative-reality gap (-28) implies traders may be underestimating risks, but the absence of panic or anchoring suggests a cautious, mimetic approach. The key question: *Will peer performance continue dictating IPSC’s trajectory, or will divergence emerge?*
Updated: 09/08/2026, 04:11 PM
What could change this?
👥 What the crowd believes
"CNTY-813 preclinical data demonstrate durable glucose control and immune evasion (Article 8)"
"Q2 EPS $(0.17) missed estimate of $(0.14) by 21.43% (Article 2)"
"Mizuho initiates Century Therapeutics at Outperform with $8 price target (Article 10)"
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Jesse Livermore — 12/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between value-oriented and growth-focused methodologies. The highest scores come from Bagehot’s liquidity focus and Graham’s defensive and enterprising frameworks, both praising its financial resilience and statistical undervaluation—suggesting it’s a safe, long-term hold for traditionalists. Meanwhile, Lynch and Marks (market cycle) see it as a growth play, with Lynch noting the price lagging behind fundamentals and Marks viewing it as early-to-mid cycle, implying upside potential. In contrast, Fisher and Livermore’s lower scores reflect skepticism: Fisher dismisses it as lacking exceptional quality, while Livermore and Schwager’s near-zero scores flag it as a trend-defying or disciplined-pass risk, warning against chasing momentum. The efficient-market camp and Loeb’s high-risk warning further split the debate, with Loeb’s caution contrasting sharply with the optimism of the value and growth camps.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 99
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 97
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 85
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 56
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 52
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 23
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 12
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 285 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-15.8%
Net Margin
-8.8%
EBITDA Margin
-15.8%
ROE
-6.0%
ROA
-4.3%
ROIC
—
EPS
-$0.14
Cash
$61.85M
Total Debt
—
Current Ratio
5.97
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$1.67
Estimated Fair Value (DCF)
-$30.87
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-130.91M | $-120.10M |
| 2 | 19.4% | $-156.27M | $-131.53M |
| 3 | 13.8% | $-177.75M | $-137.26M |
| 4 | 8.1% | $-192.20M | $-136.16M |
| 5 | 2.5% | $-197.00M | $-128.04M |
Base FCF (last actual year)
$-104.72M
Terminal Value
$-3.11B
Present Value of Terminal Value
$-2.02B
Enterprise Value
$-2.67B
Net Debt
$0
Equity Value
$-2.67B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$1.84
Tangible Book Value per Share (Tangible NAV)
$1.44
Sentiment based on basic keywords (not AI) — 3 positive, 7 neutral, 2 negative out of the last 12 articles.
GlobeNewswire · 9.9.2026
Yahoo · 9.9.2026
GlobeNewswire · 12.8.2026
Benzinga · 12.8.2026
Insider Monkey · 14.7.2026
GlobeNewswire · 9.7.2026
GlobeNewswire · 22.6.2026
Simply Wall St. · 13.6.2026
Insider Monkey · 10.6.2026
GlobeNewswire · 8.6.2026
MT Newswires · 4.6.2026
MT Newswires · 27.5.2026
Century Therapeutics, Inc. (IPSC) currently has a StockIQ AI score of 42/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
IPSC currently scores 42/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
IPSC's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 1556.8%; Earnings per share (EPS) growth: 91.3%; Net income growth: 92.4%.
Based on the real signals StockIQ computed: Operating margin: -15.8% (negative); Net margin: -8.8% (negative); ATR: 6.7% of price.
StockIQ has no recorded dividend payment history for IPSC.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 14 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Carr Douglas | Open Market Sale | 14.9.2026 | 502,907 | -1,658 | $1.93 |
| Russotti Gregory | Open Market Sale | 14.9.2026 | 509,198 | -2,587 | $1.93 |
| Russotti Gregory | Open Market Sale | 14.9.2026 | 2,587 | -2,587 | $1.93 |
| Carr Douglas | Open Market Sale | 14.9.2026 | 1,658 | -1,658 | $1.93 |
| Pfeiffenberger Brent | Tax Withholding in Shares | 11.9.2026 | 3,633,839 | -13,850 | $1.94 |
| Pfeiffenberger Brent | Tax Withholding in Shares | 11.9.2026 | 13,850 | -13,850 | $1.94 |
| Truitt Joseph | Grant/Award from Employer | 9.9.2026 | 148,000 | +148,000 | — |
| Truitt Joseph | Grant/Award from Employer | 9.9.2026 | 148,000 | +148,000 | — |
| Carr Douglas | Open Market Sale | 8.9.2026 | 504,565 | -254 | $2.05 |
| Russotti Gregory | Open Market Sale | 8.9.2026 | 511,785 | -534 | $2.05 |
| Russotti Gregory | Open Market Sale | 8.9.2026 | 534 | -534 | $2.05 |
| Carr Douglas | Open Market Sale | 8.9.2026 | 254 | -254 | $2.05 |
| Pfeiffenberger Brent | Tax Withholding in Shares | 4.9.2026 | 3,633,839 | -463 | $2.11 |
| Pfeiffenberger Brent | Tax Withholding in Shares | 4.9.2026 | 463 | -463 | $2.11 |
| Pfeiffenberger Brent | Tax Withholding in Shares | 14.8.2026 | 3,634,302 | -31,172 | $1.92 |
| Pfeiffenberger Brent | Tax Withholding in Shares | 14.8.2026 | 31,172 | -31,172 | $1.92 |
| Carr Douglas | Open Market Sale | 3.8.2026 | 275 | -275 | $1.98 |
| Carr Douglas | Open Market Sale | 3.8.2026 | 504,819 | -275 | $1.98 |
| Carr Douglas | Open Market Sale | 12.6.2026 | 1,654 | -1,654 | $2.23 |
| Russotti Gregory | Open Market Sale | 12.6.2026 | 2,584 | -2,584 | $2.23 |
| Carr Douglas | Open Market Sale | 12.6.2026 | 505,094 | -1,654 | $2.23 |
| Russotti Gregory | Open Market Sale | 12.6.2026 | 512,319 | -2,584 | $2.23 |
| Murphy Martin Patrick | Grant/Award from Employer | 11.6.2026 | 74,000 | +74,000 | — |
| Pfeiffenberger Brent | Tax Withholding in Shares | 11.6.2026 | 13,849 | -13,849 | $2.24 |
| Blackwell Kimberly | Grant/Award from Employer | 11.6.2026 | 74,000 | +74,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
29,354,630 shares short as of 2026-09-15 · vs. 29,528,941 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.3% of trading volume this week was short selling, vs. 59.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology